Coronavirus Update: Moderna Hold Up, Sanofi and Regeneron's Kevzara Fails In Phase III
IL-6 Drugs Down But Not Out
Delay to Moderna's Phase III plans adds to the biotech's rollercoaster ride, but its CEO insists it is still on track.
You may also be interested in...
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.
Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.